12-11-2020, 03:16 PM
https://www.statnews.com/2020/12/11/sano...9-vaccine/
The vaccine is a bit behind (it just concluded its phase I/II data) but as a more conventional vaccine was probably easier to make at scale and would have been more stable. Unfortunately, it did not produce an adequate immune response in older volunteers.
When, at the onset of the pandemic everyone said that in order to develop a vaccine within a year, everything would have to break correctly, this is what they meant. Setbacks like this are the rule and not the exception, so in some ways we have been lucky that both the Moderna and Pfizer vaccines were successful within the year. Still, it is a setback in the effort to build herd immunity, especially in developing countries (a lot of doses of the vaccine were tabbed to go to the developing world under the CoVax program).
BC
The vaccine is a bit behind (it just concluded its phase I/II data) but as a more conventional vaccine was probably easier to make at scale and would have been more stable. Unfortunately, it did not produce an adequate immune response in older volunteers.
Quote:The problem relates to inadequate results in older adults in Sanofi’s Phase 1/2 trial, which the company traced back to an inadequate formulation of their vaccine, Su-Peing Ng, global medical head for Sanofi Vaccines, told STAT in an interview.
Ng said both Sanofi and GSK are committed to continuing work on the vaccine, and plan to begin a Phase 2b trial in February.
When, at the onset of the pandemic everyone said that in order to develop a vaccine within a year, everything would have to break correctly, this is what they meant. Setbacks like this are the rule and not the exception, so in some ways we have been lucky that both the Moderna and Pfizer vaccines were successful within the year. Still, it is a setback in the effort to build herd immunity, especially in developing countries (a lot of doses of the vaccine were tabbed to go to the developing world under the CoVax program).
BC